Researchers use single-cell analysis to show how transplanted neural stem cells interact with the retina to preserve vision in retinitis pigmentosa.
A new CRISPR-powered light sensor can detect the faintest molecular signs of cancer in a drop of blood. A new light-based sensor can spot incredibly tiny amounts of cancer biomarkers in blood, raising the possibility of earlier and simpler cancer detection. The technology merges DNAnanotechnology, CRISPR, and quantumdots to generate a clear signal from just a few molecules. In lung cancer tests, it worked even in real patient serum samples. Researchers hope it could eventually power portable blood tests for cancer and other diseases.
Scientists have designed a powerful light based sensor capable of detecting extremely small amounts of cancer biomarkers in blood. The innovation could eventually allow doctors to identify early warning signs of cancer and other diseases through a routine blood draw.
Biomarkers such as proteins, fragments of DNA, and other molecules can signal whether cancer is present, how it is progressing, or a person’s risk of developing it. The difficulty is that in the earliest stages of disease, these markers exist in extremely low concentrations, making them hard to measure with conventional tools.
Wang et al. systematically analyzed mitochondria-localized lncRNAs to reveal that RBP-motif recognition drives RNA mitochondrial translocation, leading to the engineering of an RNA mitochondrial targeting sequence (RMTS). Fusing RMTS with sgRNA promotes sgRNA mitochondrial entry, establishing a CRISPR-based mitochondrial DNA editing system that ameliorates heteroplasmic mtDNA mutation diseases.
DNA is the blueprint of life. Genes encode proteins and serve as the body’s basic components. However, building a functioning organism also requires precise instructions about when, where, and how much those components should be produced. This layer of control is carried out by cis-regulatory elements (CREs), which are short stretches of DNA that serve as binding sites for transcription factors and help control the activity of nearby genes, hence are often described as the “switches” and “dials” of genes. Although CREs do not encode proteins themselves, they play a major role in shaping traits, guiding development, and influencing disease risk.
CREs control gene expression through epigenetic mechanisms, such as whether DNA is open and accessible and whether it carries markers associated with active gene regulation. Even small changes in CRE sequences can have substantial effect on gene expression. Until now, scientists have relied on separate experimental methods to study these processes. Some methods identify DNA regions that appear to function as regulatory elements, while others test whether a DNA sequence can activate gene expression. Because these approaches are usually performed independently in different experiments, it has been difficult to directly connect cause and effect or to systematically evaluate the impact of individual changes in the sequence.
To overcome these limitations, the researchers developed an enrichment followed by epigenomic profiling massively parallel reporter assay (e2MPRA), a new technique that builds on their earlier lentiMPRA platform, which enables simultaneous analysis of thousands of CREs by tagging them with unique DNA barcodes that track their activity. e2MPRA takes this technique a step further by also capturing epigenetic states, allowing researchers to directly link what a CRE does with how it does it under identical experimental conditions.
E2MPRA was validated using two large libraries totaling approximately 10,000 sequences: one consisted of synthetic CREs with systematically arranged transcription factor binding sites, and the other contained known CREs in which small DNA changes were introduced to examine how each alteration affected function. For each CRE, the researchers measured three key features: how strongly it activates genes (regulatory activity), whether the surrounding DNA is open and accessible (chromatin accessibility), and whether it carries a chemical “active” mark (H3K27ac modification).
Using this approach, the team demonstrated that different CREs regulate genes in distinct ways. Some primarily boost gene activity without substantially altering DNA structure, while others mainly increase DNA accessibility. The researchers also found that the arrangement and order of the binding sites within a CRE can strongly influence its activity, much like word order can change the meaning of a sentence.
The team then used e2MPRA to examine how tiny DNA changes (as tiny as a single “letter” difference) can disrupt gene regulation. In regions containing the POU5F1::SOX2 binding site, which plays a key role in maintaining stem cell identity, mutations altered not only gene activity but also DNA accessibility and H3K27ac levels.
In contrast, changes in the YY1 binding site showed a more complex behavior: mutations reduced gene activity but increased DNA accessibility. These findings show that DNA variants can influence gene regulation through multiple, overlapping layers rather than through a simple on–off mechanism. ScienceMission sciencenewshighlights.
A new study from the University of Helsinki reveals how plant mitochondria draw molecular oxygen away from chloroplasts, an interaction not previously documented. The discovery sheds new light on how plants regulate oxygen inside their tissues, with implications for understanding plant metabolism and stress acclimation. The research, led by Dr. Alexey Shapiguzov (Ph. D., Docent) from the University’s Centre of Excellence in Tree Biology on the Viikki campus, has been published in Plant Physiology.
Oxygen gas is central to plant metabolism, growth, stress acclimation and immunity. Recent research at the University of Helsinki has shown that oxygen triggers wound healing in plants. Yet, despite its importance, scientists still lack an understanding of how oxygen levels inside plant tissues are controlled.
In plant cells, oxygen dynamics are dominated by two organelles: mitochondria that consume oxygen during respiration, and chloroplasts that produce oxygen as a by-product of photosynthesis.
Kanabar SS, Pavord ID, Hinks TSC. Respir Med. 2026 Feb 26:108736. doi: 10.1016/j.rmed.2026.108736. Highlights • Asthma is a heterogeneous condition due to multiple biological processes. • Individual treatable traits are identifiable and responsive to treatment. • Extra-pulmonary traits are important to consider and address. Abstract In the era of personalised medicine, approaches to asthma assessment
Learn more about this fascinating technique which is coming to cardiovascular medicine:
Paper:
Podcast with the authors: https://bit.ly/49oxvq9
Photon-counting CT (PCCT) represents a transformative advancement in cardiac imaging, addressing key limitations of conventional CT. This review synthesises current evidence to demonstrate how PCCT’s superior spatial resolution, enhanced tissue characterisation and multienergy capabilities broaden the diagnostic potential of cardiac CT. Applications include the precise detection and quantification of coronary artery calcifications, evaluation of coronary plaque burden and composition, improved assessment of coronary stents, and comprehensive myocardial tissue characterisation and perfusion analysis. By offering high-quality spectral information and detailed tissue characterisation, PCCT provides a non-invasive alternative for assessing coronary artery disease and myocardial pathology, reducing the need for invasive coronary angiography and cardiac MRI.
This phase 2 nonrandomized clinical trial evaluated oral upadacitinib for severe immune checkpoint inhibitor–related dermatitis in patients with solid tumors.
Rash resolution to grade ≤1 was achieved in all participants within 28 days, and pruritus improvement was reported within 1 day of initiation. Upadacitinib was well tolerated, with no serious treatment-related adverse events.
The majority of patients were able to continue immune checkpoint inhibitor therapy as scheduled, indicating the potential of upadacitinib as a safe and effective option for managing severe Dermatitis induced by immunotherapy.
This nonrandomized clinical trial examines the safety and efficacy of oral upadacitinib in the treatment of patients with severe immune checkpoint inhibitor–related dermatitis.
[Alzheimer’s disease: AD] Zhang et al.: “Increased theta band power was statistically significant in AD patients, highlighting its critical role in AD pathology.”
Your browser extensions or network settings have blocked the security verification process required by www.sciencedirect.com. To resolve this, try the following steps:
Temporarily disable browser extensions: